Search

Your search keyword '"Nakanishi, Yoichi"' showing total 500 results
Start Over Author "Nakanishi, Yoichi" Database Unpaywall
500 results on '"Nakanishi, Yoichi"'

2. Prognosis and management of chronic obstructive pulmonary disease in a real-world setting: A 5-year follow-up analysis of a multi-institutional registry

Author

Takano, Tomotsugu, primary, Tsubouchi, Kazuya, additional, Hamada, Naoki, additional, Ichiki, Katsuyuki, additional, Torii, Ryo, additional, Takata, Shohei, additional, Kawakami, Satoru, additional, Nakagaki, Noriaki, additional, Yoshida, Makoto, additional, Kitasato, Yasuhiko, additional, Tobino, Kazunori, additional, Harada, Eiji, additional, Ishii, Hiroshi, additional, Wataya, Hiroshi, additional, Maeyama, Takashige, additional, Fujita, Masaki, additional, Yatera, Kazuhiro, additional, Okamoto, Masaki, additional, Yabuuchi, Hidetake, additional, Kiyomi, Fumiaki, additional, Tokunaga, Shoji, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2024
Full Text
View/download PDF

4. Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry

Author

Tsubouchi, Kazuya, primary, Hamada, Naoki, additional, Tokunaga, Shoji, additional, Ichiki, Katsuyuki, additional, Takata, Shohei, additional, Ishii, Hiroshi, additional, Kitasato, Yasuhiko, additional, Okamoto, Masaki, additional, Kawakami, Satoru, additional, Yatera, Kazuhiro, additional, Kawasaki, Masayuki, additional, Fujita, Masaki, additional, Yoshida, Makoto, additional, Maeyama, Takashige, additional, Harada, Taishi, additional, Wataya, Hiroshi, additional, Torii, Ryo, additional, Komori, Masashi, additional, Mizuta, Yuichi, additional, Tobino, Kazunori, additional, Harada, Eiji, additional, Yabuuchi, Hidetake, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2023
Full Text
View/download PDF

6. Five-year follow up analysis of Japanese ILD registry

Author

Tsubouchi, Kazuya, primary, Hamada, Naoki, additional, Tokunaga, Shoji, additional, Tsuda, Toru, additional, Takata, Shohei, additional, Ishii, Hiroshi, additional, Kitasato, Yasuhiko, additional, Hoshino, Tomoaki, additional, Sasahara, Yosuke, additional, Yatera, Kazuhiro, additional, Kawasaki, Masayuki, additional, Fujita, Masaki, additional, Yoshida, Makoto, additional, Maeyama, Takashige, additional, Harada, Taishi, additional, Wataya, Hiroshi, additional, Yoshii, Chiharu, additional, Komori, Masashi, additional, Mizuta, Yuichi, additional, Tobino, Kazunori, additional, Harada, Eiji, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2023
Full Text
View/download PDF

8. Data from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

9. Data from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

10. ntary Methods, Figure Legends from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

11. ntary Methods, Figure Legends from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures 1 - 7 from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figures 1 - 7 from TLR7 Ligand Augments GM-CSF–Initiated Antitumor Immunity through Activation of Plasmacytoid Dendritic Cells

Author

Narusawa, Megumi, primary, Inoue, Hiroyuki, primary, Sakamoto, Chika, primary, Matsumura, Yumiko, primary, Takahashi, Atsushi, primary, Inoue, Tomoko, primary, Watanabe, Ayumi, primary, Miyamoto, Shohei, primary, Miura, Yoshie, primary, Hijikata, Yasuki, primary, Tanaka, Yoshihiro, primary, Inoue, Makoto, primary, Takayama, Koichi, primary, Okazaki, Toshihiko, primary, Hasegawa, Mamoru, primary, Nakanishi, Yoichi, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Author

Ota, Keiichi, primary, Azuma, Koichi, primary, Kawahara, Akihiko, primary, Hattori, Satoshi, primary, Iwama, Eiji, primary, Tanizaki, Junko, primary, Harada, Taishi, primary, Matsumoto, Koichiro, primary, Takayama, Koichi, primary, Takamori, Shinzo, primary, Kage, Masayoshi, primary, Hoshino, Tomoaki, primary, Nakanishi, Yoichi, primary, and Okamoto, Isamu, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure S2 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Author

Ota, Keiichi, primary, Azuma, Koichi, primary, Kawahara, Akihiko, primary, Hattori, Satoshi, primary, Iwama, Eiji, primary, Tanizaki, Junko, primary, Harada, Taishi, primary, Matsumoto, Koichiro, primary, Takayama, Koichi, primary, Takamori, Shinzo, primary, Kage, Masayoshi, primary, Hoshino, Tomoaki, primary, Nakanishi, Yoichi, primary, and Okamoto, Isamu, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Author

Ota, Keiichi, primary, Azuma, Koichi, primary, Kawahara, Akihiko, primary, Hattori, Satoshi, primary, Iwama, Eiji, primary, Tanizaki, Junko, primary, Harada, Taishi, primary, Matsumoto, Koichiro, primary, Takayama, Koichi, primary, Takamori, Shinzo, primary, Kage, Masayoshi, primary, Hoshino, Tomoaki, primary, Nakanishi, Yoichi, primary, and Okamoto, Isamu, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure S3 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Author

Ota, Keiichi, primary, Azuma, Koichi, primary, Kawahara, Akihiko, primary, Hattori, Satoshi, primary, Iwama, Eiji, primary, Tanizaki, Junko, primary, Harada, Taishi, primary, Matsumoto, Koichiro, primary, Takayama, Koichi, primary, Takamori, Shinzo, primary, Kage, Masayoshi, primary, Hoshino, Tomoaki, primary, Nakanishi, Yoichi, primary, and Okamoto, Isamu, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table S1 from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Author

Ota, Keiichi, primary, Azuma, Koichi, primary, Kawahara, Akihiko, primary, Hattori, Satoshi, primary, Iwama, Eiji, primary, Tanizaki, Junko, primary, Harada, Taishi, primary, Matsumoto, Koichiro, primary, Takayama, Koichi, primary, Takamori, Shinzo, primary, Kage, Masayoshi, primary, Hoshino, Tomoaki, primary, Nakanishi, Yoichi, primary, and Okamoto, Isamu, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

20. Data from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 3 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

27. Data from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 4 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure Legends 1-5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 4 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legends 1-5 from Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

Author

Miyamoto, Shohei, primary, Inoue, Hiroyuki, primary, Nakamura, Takafumi, primary, Yamada, Meiko, primary, Sakamoto, Chika, primary, Urata, Yasuo, primary, Okazaki, Toshihiko, primary, Marumoto, Tomotoshi, primary, Takahashi, Atsushi, primary, Takayama, Koichi, primary, Nakanishi, Yoichi, primary, Shimizu, Hiroyuki, primary, and Tani, Kenzaburo, primary

Published
2023
Full Text
View/download PDF

35. Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer

Author

Tanaka, Kentaro, primary, Chamoto, Kenji, additional, Saeki, Sho, additional, Hatae, Ryusuke, additional, Ikematsu, Yuki, additional, Sakai, Kazuko, additional, Ando, Nobuhisa, additional, Sonomura, Kazuhiro, additional, Kojima, Shinsuke, additional, Taketsuna, Masanori, additional, Kim, Young Hak, additional, Yoshida, Hironori, additional, Ozasa, Hiroaki, additional, Sakamori, Yuichi, additional, Hirano, Tomoko, additional, Matsuda, Fumihiko, additional, Hirai, Toyohiro, additional, Nishio, Kazuto, additional, Sakagami, Takuro, additional, Fukushima, Masanori, additional, Nakanishi, Yoichi, additional, Honjo, Tasuku, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

37. Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment

Author

Yoneshima, Yasuto, primary, Morita, Satoshi, additional, Ando, Masahiko, additional, Nakamura, Atsushi, additional, Iwasawa, Shunichiro, additional, Yoshioka, Hiroshige, additional, Goto, Yasuhiro, additional, Takeshita, Masafumi, additional, Harada, Toshiyuki, additional, Hirano, Katsuya, additional, Oguri, Tetsuya, additional, Kondo, Masashi, additional, Miura, Satoru, additional, Hosomi, Yukio, additional, Kato, Terufumi, additional, Kubo, Toshio, additional, Kishimoto, Junji, additional, Yamamoto, Nobuyuki, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

39. Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade

Author

Takada, Kazuki, primary, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Shimokawa, Mototsugu, additional, Takamori, Shinkichi, additional, Matsubara, Taichi, additional, Takenaka, Tomoyoshi, additional, Okamoto, Tatsuro, additional, Hamatake, Motoharu, additional, Tsuchiya-Kawano, Yuko, additional, Otsubo, Kohei, additional, Nakanishi, Yoichi, additional, Okamoto, Isamu, additional, Pinato, David J., additional, Cortellini, Alessio, additional, and Yoshizumi, Tomoharu, additional

Published
2022
Full Text
View/download PDF

42. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Author

Takada, Kazuki, primary, Shimokawa, Mototsugu, additional, Takamori, Shinkichi, additional, Shimamatsu, Shinichiro, additional, Hirai, Fumihiko, additional, Tagawa, Tetsuzo, additional, Okamoto, Tatsuro, additional, Hamatake, Motoharu, additional, Tsuchiya-Kawano, Yuko, additional, Otsubo, Kohei, additional, Inoue, Koji, additional, Yoneshima, Yasuto, additional, Tanaka, Kentaro, additional, Okamoto, Isamu, additional, Nakanishi, Yoichi, additional, and Mori, Masaki, additional

Published
2022
Full Text
View/download PDF

43. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

Author

Otsubo, Kohei, primary, Kishimoto, Junji, additional, Ando, Masahiko, additional, Kenmotsu, Hirotsugu, additional, Minegishi, Yuji, additional, Horinouchi, Hidehito, additional, Kato, Terufumi, additional, Ichihara, Eiki, additional, Kondo, Masashi, additional, Atagi, Shinji, additional, Tamiya, Motohiro, additional, Ikeda, Satoshi, additional, Harada, Toshiyuki, additional, Takemoto, Shinnosuke, additional, Hayashi, Hidetoshi, additional, Nakatomi, Keita, additional, Kimura, Yuichiro, additional, Kondoh, Yasuhiro, additional, Kusumoto, Masahiko, additional, Ichikado, Kazuya, additional, Yamamoto, Nobuyuki, additional, Nakagawa, Kazuhiko, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

45. Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations

Author

Iwama, Eiji, primary, Zenke, Yoshitaka, additional, Sugawara, Shunichi, additional, Daga, Haruko, additional, Morise, Masahiro, additional, Yanagitani, Noriko, additional, Sakamoto, Tomohiro, additional, Murakami, Haruyasu, additional, Kishimoto, Junji, additional, Matsumoto, Shingo, additional, Nakanishi, Yoichi, additional, Goto, Koichi, additional, and Okamoto, Isamu, additional

Published
2022
Full Text
View/download PDF

48. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

Author

Yoneshima, Yasuto, primary, Morita, Satoshi, additional, Ando, Masahiko, additional, Nakamura, Atsushi, additional, Iwasawa, Shunichiro, additional, Yoshioka, Hiroshige, additional, Goto, Yasuhiro, additional, Takeshita, Masafumi, additional, Harada, Toshiyuki, additional, Hirano, Katsuya, additional, Oguri, Tetsuya, additional, Kondo, Masashi, additional, Miura, Satoru, additional, Hosomi, Yukio, additional, Kato, Terufumi, additional, Kubo, Toshio, additional, Kishimoto, Junji, additional, Yamamoto, Nobuyuki, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2021
Full Text
View/download PDF

49. Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission

Author

Ninomiya, Toshifumi, primary, Otsubo, Kohei, additional, Hoshino, Teppei, additional, Shimokawa, Mototsugu, additional, Nakazawa, Megumi, additional, Sato, Yoriko, additional, Mikumo, Hironori, additional, Kawakami, Satoru, additional, Mizusaki, Shun, additional, Mori, Yusuke, additional, Arimura, Hidenobu, additional, Tsuchiya-Kawano, Yuko, additional, Inoue, Koji, additional, Uchida, Yujiro, additional, and Nakanishi, Yoichi, additional

Published
2021
Full Text
View/download PDF

50. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib

Author

Liu, Renpeng, primary, Ota, Keiichi, additional, Iwama, Eiji, additional, Yoneshima, Yasuto, additional, Tanaka, Kentaro, additional, Inoue, Hiroyuki, additional, Tagawa, Tetsuzo, additional, Oda, Yoshinao, additional, Mori, Masaki, additional, Nakanishi, Yoichi, additional, and Okamoto, Isamu, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results